Company: TYRA
Filing Date: 2025-01-29
Form Type: 8-K
Source: 0001193125-25-015646
Chunk: 1

Company: Tyra Biosciences, Inc.
Filing Date: 2025-01-29
Form: 8-K
Item: Item 5.02
Chunk 1
---
 Pfizer’s U. S. biopharmaceutical businesses, including Speciality, Oncology and Vaccines, and as Pfizer’s President of Latin America. Prior to joining Pfizer, she held executive positions at AstraZeneca Pharmaceuticals, including running the cardiovascular business unit where she led the launch of CRESTOR®, and at the Parke-Davis division of Warner-Lambert Company (which later merged with Pfizer) she served as the Senior Director, Cardiovascular Marketing and led the launch of LIPITOR®. Ms. Gulfo currently serves as a member of the board of directors of Enpro Inc. and previously served on the boards of directors of Myovant Sciences, Bemis Company, Inc. (acquired by Amcor plc) and Medexus Pharmaceuticals Inc. She also currently serves on the Innovation Growth Board for Mass General Brigham. Ms. Gulfo holds a Bachelor of Science in Biology from Seton Hall University and an MBA in Marketing from Fairleigh Dickinson University.

In connection with her appointment to the Board, pursuant to the Company’s Non-EmployeeDirector Compensation Program, Ms. Gulfo was granted options to purchase 37,200 shares of the Company’s common stock. The options have an exercise price per share equal to the fair market value of the Company’s common stock on the date of grant. The foregoing awards will vest in substantially equal monthly installments over the thirty-sixmonths following the date of grant. Ms. Gulfo will also receive cash compensation for her service on the Board and committees thereof in accordance with the Company’s Non-EmployeeDirector Compensation Program, as such program may be amended from time to time.

Further, in connection with her appointment to the Board, Ms. Gulfo entered into the Company’s standard form of indemnification agreement, the form of which has been filed with the Company’s most recent annual report on Form10-K.

There are no arrangements or understandings between Ms. Gulfo and any other person pursuant to which she was selected to serve on the Board. There are no transactions in which the Company or any of its subsidiaries is a party and in which Ms. Gulfo has a material interest subject to disclosure under Item 404(a) of Regulation S-K. The Board has determined that Ms. Gulfo is an independent director in accordance with the listing requirements of The Nasdaq Stock Market LLC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned